These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20432331)

  • 21. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
    de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
    Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
    White WM; Pickens RB; Doggweiler R; Klein FA
    J Urol; 2008 Dec; 180(6):2522-6. PubMed ID: 18930481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
    Sahai A; Dowson C; Khan MS; Dasgupta P
    BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
    [No Abstract]   [Full Text] [Related]  

  • 24. Botulinum toxin a in the overactive bladder: current status and future directions.
    Mallina R; Sahai A; Khan MS; Dasgupta P
    BJU Int; 2007 Jun; 99(6):1549-50. PubMed ID: 17537223
    [No Abstract]   [Full Text] [Related]  

  • 25. Botulinum toxin--new mechanisms, new therapeutic directions?
    Chapple C; Patel A
    Eur Urol; 2006 Apr; 49(4):606-8. PubMed ID: 16457945
    [No Abstract]   [Full Text] [Related]  

  • 26. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study.
    Mehnert U; Birzele J; Reuter K; Schurch B
    J Urol; 2010 Sep; 184(3):1011-6. PubMed ID: 20643431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.
    Stoehrer M; Wolff A; Kramer G; Steiner R; Lmöchner-Ernst D; Leuth D; Steude U; Ruebben H
    Urol Int; 2009; 83(4):379-85. PubMed ID: 19996642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
    Sahai A; Dowson C; Khan MS; Dasgupta P
    BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin A in the overactive bladder: current status and future directions.
    Dmochowski R; Sand PK
    BJU Int; 2007 Feb; 99(2):247-62. PubMed ID: 17313422
    [No Abstract]   [Full Text] [Related]  

  • 31. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity.
    Drake MJ
    BJU Int; 2008 Jul; 102 Suppl 1():11-6. PubMed ID: 18665973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.
    Cruz F; Dinis P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):920-7. PubMed ID: 17705161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease.
    Kulaksizoglu H; Parman Y
    Parkinsonism Relat Disord; 2010 Sep; 16(8):531-4. PubMed ID: 20637678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
    Antunes AA; Srougi M; Coelho RF; de Campos Freire G
    Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
    Schulte-Baukloh H; Weiss C; Stolze T; Stürzebecher B; Knispel HH
    Urology; 2005 Jul; 66(1):82-7. PubMed ID: 15992872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
    BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
    Sahai A; Khan MS; Dasgupta P
    J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Wyndaele JJ
    Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of neurogenic incontinence with botulinum toxin A.
    Schurch B; Schmid DM; Stöhrer M
    N Engl J Med; 2000 Mar; 342(9):665. PubMed ID: 10702067
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.